All In Biotech

Drug Trial Radar · NCT06580314

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

880

Planned (sponsor's estimate)

Start

Mar 12, 2025

Primary completion

Dec 31, 2034

Study completion Dec 31, 2034

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Conditions

  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
  • FIGO Stage III Ovarian Cancer 2014
  • FIGO Stage IV Ovarian Cancer 2014
  • Ovarian Carcinoma
  • Ovarian Carcinosarcoma
  • Ovarian High Grade Endometrioid Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal Carcinosarcoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • OlaparibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) at least 360 days after randomization (PFS360)Time frame: From completing 360 days of maintenance therapy to disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) or death, whichever occurs first, assessed up to 5 years

Locations

709 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Recruiting

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Recruiting

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Recruiting

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Recruiting

  • Katmai Oncology Group

    Anchorage, Alaska · Recruiting

  • Providence Alaska Medical Center

    Anchorage, Alaska · Recruiting

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • CARTI Cancer Center

    Little Rock, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California · Recruiting

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Active not recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Recruiting

  • Mills-Peninsula Medical Center

    Burlingame, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California · Recruiting

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • Eden Hospital Medical Center

    Castro Valley, California · Recruiting

  • Sutter Davis Hospital

    Davis, California · Recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California · Recruiting

  • Stanford Cancer Center Emeryville

    Emeryville, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Palo Alto Medical Foundation-Fremont

    Fremont, California · Recruiting

  • Fresno Cancer Center

    Fresno, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Recruiting

  • Kaiser Permanente South Bay

    Harbor City, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

Showing 40 of 709 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.